(RTTNews) - Eli Lilly and Co. (LLY) announced that the U.S. Food and Drug Administration has approved Omvoh (mirikizumab-mrkz) for the treatment of moderately to severely active Crohn's disease in ...
Omvoh is now approved in the U.S. for two types of inflammatory bowel disease (IBD), following its October 2023 approval as a first-in-class treatment for moderately to severely active ulcerative ...
THURSDAY, Jan. 16, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Omvoh (mirikizumab-mrkz) for the treatment of moderately to severely active Crohn disease in adults ...
Please provide your email address to receive an email when new articles are posted on . The FDA has approved Omvoh for the treatment of moderately to severely active Crohn’s disease, making it ...
Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The FDA expanded the approval of mirikizumab (Omvoh) to include treatment of adults with moderately to severely active ...
(RTTNews) - Eli Lilly and Co. (LLY), on Friday, announced that most patients with moderately to severely active Crohn's disease treated with Omvoh for two years, experienced sustained clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results